8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Mar 24, 2026·SEC
QuidelOrtho Corporation(QDEL)Earnings, Financials & Key Ratios
QDEL•NASDAQ
Price updated Jun 19, 2026
AboutQuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.Show more
- Revenue$2.73B-1.9%
- EBITDA-$477M+68.3%
- Net Income-$1.13B+44.8%
- EPS (Diluted)-16.69+45.4%
- Gross Margin46.67%+1.0%
- EBITDA Margin-17.48%+67.7%
- Operating Margin-33.67%+52.2%
- Net Margin-41.45%+43.8%
- ROE-46.15%+10.1%
QDEL Key Insights
QuidelOrtho Corporation (QDEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 10.4%
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when QDEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QDEL Price & Volume
QuidelOrtho Corporation (QDEL) stock price & volume — 10-year historical chart
Loading chart...
QDEL Growth Metrics
QuidelOrtho Corporation (QDEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years30.13%
5 Years10.44%
3 Years-5.8%
TTM-3.89%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-237.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-259.15%
Return on Capital
10 Years13.87%
5 Years4.14%
3 Years-15.33%
Last Year-17.97%
QDEL Recent Earnings
QuidelOrtho Corporation (QDEL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.04-110.8%
$0.37
Rev
$620M-6.8%
$665M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$0.46+7.0%
$0.43
Rev
$724M+3.3%
$701M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.80+56.9%
$0.51
Rev
$700M-0.0%
$700M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.12-78.6%
$0.56
Rev
$615M-9.1%
$676M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.04vs $0.37-110.8% | $620Mvs $665M-6.8% |
| Q1 2026 | Feb 11, 2026 | $0.46vs $0.43+7.0% | $724Mvs $701M+3.3% |
| Q4 2025 | Nov 5, 2025 | $0.80vs $0.51+56.9% | $700Mvs $700M-0.0% |
| Q3 2025 | Aug 5, 2025 | $0.12vs $0.56-78.6% | $615Mvs $676M-9.1% |
Based on last 12 quarters of dataView full earnings history →
QDEL Peer Comparison
QuidelOrtho Corporation (QDEL) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 ALGN | 13.04B | 182.08 | 32.23 | 0.9% | 10.5% | 10.7% | 0.03 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare QDEL vs Peers
QuidelOrtho Corporation (QDEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QDEL Income Statement
QuidelOrtho Corporation (QDEL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Jan'23 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 277.74M | 522.28M | 534.89M | 1.66B | 1.7B | 3.27B | 3B | 2.78B | 2.73B | 2.66B |
Revenue Growth % | 44.96% | 88.05% | 2.41% | 210.66% | 2.22% | 92.28% | -8.21% | -7.17% | -1.89% | -3.89% |
Cost of Goods Sold | 121.6M | 206.57M | 214.09M | 312.81M | 420.3M | 1.33B | 1.5B | 1.5B | 1.46B | 1.15B |
COGS % of Revenue | 43.78% | 39.55% | 40.02% | 18.83% | 24.74% | 40.72% | 50.06% | 53.77% | 53.33% | - |
Gross Profit | 156.14M▲ 0% | 315.71M▲ 102.2% | 320.81M▲ 1.6% | 1.35B▲ 320.5% | 1.28B▼ 5.2% | 1.94B▲ 51.5% | 1.5B▼ 22.7% | 1.29B▼ 14.1% | 1.27B▼ 1.0% | 1.5B▲ 0% |
Gross Margin % | 56.22% | 60.45% | 59.98% | 81.17% | 75.26% | 59.28% | 49.94% | 46.23% | 46.67% | 56.6% |
Gross Profit Growth % | 32.11% | 102.2% | 1.61% | 320.46% | -5.23% | 51.47% | -22.68% | -14.07% | -0.96% | - |
Operating Expenses | 130.08M | 205.59M | 228.09M | 288.53M | 372.3M | 1.09B | 1.36B | 3.25B | 2.19B | 2.13B |
OpEx % of Revenue | 46.84% | 39.36% | 42.64% | 17.36% | 21.92% | 33.45% | 45.3% | 116.69% | 80.34% | - |
Selling, General & Admin | 96.44M | 153.94M | 163.87M | 200.54M | 239.6M | 621M | 763.2M | 766.8M | 746.3M | 758.6M |
SG&A % of Revenue | 34.72% | 29.47% | 30.64% | 12.07% | 14.11% | 19.01% | 25.46% | 27.55% | 27.33% | - |
Research & Development | 33.64M | 51.65M | 52.55M | 84.29M | 95.7M | 187.9M | 246.8M | 218.7M | 186.2M | 177.9M |
R&D % of Revenue | 12.11% | 9.89% | 9.83% | 5.07% | 5.63% | 5.75% | 8.23% | 7.86% | 6.82% | - |
Other Operating Expenses | 0 | 0 | 11.67M | 3.69M | 37M | 283.6M | 349.8M | 2.26B | 1.26B | 3M |
Operating Income | 9.55M▲ 0% | 95.93M▲ 904.3% | 92.72M▼ 3.3% | 1.06B▲ 1043.6% | 906M▼ 14.6% | 843.7M▼ 6.9% | 139.1M▼ 83.5% | -1.96B▼ 1509.7% | -919.2M▲ 53.1% | -983.6M▲ 0% |
Operating Margin % | 3.44% | 18.37% | 17.33% | 63.81% | 53.34% | 25.83% | 4.64% | -70.46% | -33.67% | -37.02% |
Operating Income Growth % | 315.18% | 904.28% | -3.35% | 1043.63% | -14.55% | -6.88% | -83.51% | -1509.71% | 53.12% | - |
EBITDA | 40.31M | 142.19M | 140.54M | 1.11B | 958.7M | 1.13B | 596.3M | -1.51B | -477.2M | -648.7M |
EBITDA Margin % | 14.51% | 27.23% | 26.28% | 66.77% | 56.44% | 34.52% | 19.89% | -54.17% | -17.48% | -24.41% |
EBITDA Growth % | 46.97% | 252.72% | -1.16% | 689.38% | -13.59% | 17.59% | -47.1% | -352.81% | 68.34% | -335.63% |
D&A (Non-Cash Add-back) | 30.76M | 46.27M | 47.83M | 49.09M | 52.7M | 283.6M | 457.2M | 453.4M | 442M | 334.9M |
EBIT | 9.55M | 87.67M | 91.97M | 1.05B | 900.6M | 810.4M | 149.8M | -1.94B | -930.1M | -965.1M |
Net Interest Income | -17.59M | -24.28M | -14.79M | -1.26M | -400K | -73.2M | -176.7M | -188.9M | -177.6M | -129.1M |
Interest Income | 0 | 0 | 0 | 0 | 300K | 1.3M | 2.2M | 0 | 0 | 6.2M |
Interest Expense | 17.59M | 24.28M | 14.79M | 1.26M | 700K | 74.5M | 178.9M | 188.3M | 177.6M | 186.4M |
Other Income/Expense | -17.59M | -32.55M | -15.54M | -20.01M | -5.7M | -107.8M | -168.2M | -170.6M | -188.5M | -194.8M |
Pretax Income | -8.04M▲ 0% | 63.38M▲ 888.8% | 77.18M▲ 21.8% | 1.04B▲ 1247.9% | 900.3M▼ 13.5% | 735.9M▼ 18.3% | -29.1M▼ 104.0% | -2.13B▼ 7224.7% | -1.11B▲ 48.0% | -1.18B▲ 0% |
Pretax Margin % | -2.89% | 12.14% | 14.43% | 62.61% | 53% | 22.53% | -0.97% | -76.59% | -40.57% | -44.35% |
Income Tax | 129K | -10.8M | 4.26M | 230.03M | 196.1M | 187.2M | -19M | -79.5M | 24.1M | 32.5M |
Effective Tax Rate % | -1.61% | -17.04% | 5.52% | 22.11% | 21.78% | 25.44% | 65.29% | 3.73% | -2.18% | -2.76% |
Net Income | -8.16M▲ 0% | 74.18M▲ 1008.5% | 72.92M▼ 1.7% | 810.29M▲ 1011.2% | 704.2M▼ 13.1% | 548.7M▼ 22.1% | -10.1M▼ 101.8% | -2.05B▼ 20216.8% | -1.13B▲ 44.8% | -1.21B▲ 0% |
Net Margin % | -2.94% | 14.2% | 13.63% | 48.76% | 41.46% | 16.8% | -0.34% | -73.74% | -41.45% | -45.57% |
Net Income Growth % | 40.87% | 1008.55% | -1.7% | 1011.18% | -13.09% | -22.08% | -101.84% | -20216.83% | 44.84% | -237.58% |
Net Income (Continuing) | -8.16M | 74.18M | 72.92M | 810.29M | 704.2M | 548.7M | -10.1M | -2.05B | -1.13B | -1.21B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.24▲ 0% | 1.74▲ 825.0% | 1.73▼ 0.6% | 18.60▲ 975.1% | 16.43▼ 11.7% | 9.56▼ 41.8% | -0.15▼ 101.6% | -30.54▼ 20260.0% | -16.69▲ 45.4% | -17.76▲ 0% |
EPS Growth % | 42.86% | 825% | -0.57% | 975.14% | -11.67% | -41.81% | -101.57% | -20260% | 45.35% | -259.15% |
EPS (Basic) | -0.24 | 1.74 | 1.78 | 19.24 | 16.74 | 9.66 | -0.15 | -30.54 | -16.69 | - |
Diluted Shares Outstanding | 33.73M | 42.55M | 43.11M | 43.59M | 42.87M | 57.4M | 66.8M | 67.2M | 67.8M | 68.2M |
Basic Shares Outstanding | 33.73M | 42.55M | 40.86M | 42.12M | 42.08M | 56.8M | 66.8M | 67.2M | 67.8M | 68.2M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
QDEL Balance Sheet
QuidelOrtho Corporation (QDEL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Jan'23 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 331.23M | 193.4M | 222.23M | 1.14B | 1.44B | 1.58B | 1.31B | 1.22B | 1.45B | 1.38B |
Cash & Short-Term Investments | 36.09M | 43.7M | 52.77M | 489.94M | 828.5M | 345M | 167.3M | 98.3M | 202.2M | 140.4M |
Cash Only | 36.09M | 43.7M | 52.77M | 489.94M | 802.8M | 292.9M | 118.9M | 98.3M | 169.8M | 140.4M |
Short-Term Investments | 0 | 0 | 0 | 0 | 25.7M | 52.1M | 48.4M | 0 | 32.4M | 0 |
Accounts Receivable | 78.36M | 76.89M | 102.35M | 529.17M | 393.8M | 586.4M | 488.4M | 451.3M | 417M | 359.9M |
Days Sales Outstanding | 102.98 | 53.73 | 69.84 | 116.24 | 84.62 | 65.53 | 59.47 | 59.19 | 55.75 | 57.93 |
Inventory | 67.08M | 67.38M | 58.09M | 113.8M | 198.8M | 524.1M | 577.8M | 533.7M | 577.6M | 611.5M |
Days Inventory Outstanding | 201.34 | 119.05 | 99.03 | 132.78 | 172.64 | 143.85 | 140.53 | 130.18 | 144.8 | 188.43 |
Other Current Assets | 146.81M | 928K | 4.45M | 2.16M | 4.6M | 22.9M | 10M | 58.3M | 0 | 265.2M |
Total Non-Current Assets | 604.02M | 612.97M | 688.64M | 728.76M | 990.1M | 7.28B | 7.25B | 5.2B | 4.32B | 4.25B |
Property, Plant & Equipment | 61.59M | 73.9M | 171.88M | 211.03M | 476.8M | 1.52B | 1.61B | 1.55B | 1.51B | 1.5B |
Fixed Asset Turnover | 4.51x | 7.07x | 3.11x | 7.87x | 3.56x | 2.15x | 1.86x | 1.80x | 1.80x | 1.78x |
Goodwill | 337.03M | 337.02M | 337.02M | 337.03M | 337M | 2.48B | 2.49B | 649.5M | 0 | 0 |
Intangible Assets | 203.83M | 175.03M | 148.11M | 122.43M | 98.7M | 3.12B | 2.93B | 2.74B | 2.56B | 2.52B |
Long-Term Investments | 0 | 0 | 0 | 0 | 37.9M | 21M | 7.4M | 21.7M | 0 | 0 |
Other Non-Current Assets | 1.58M | 4.83M | 7.13M | 13.51M | 19.6M | 122.7M | 179.6M | 249M | 244.4M | 234.2M |
Total Assets | 935.25M▲ 0% | 806.37M▼ 13.8% | 910.87M▲ 13.0% | 1.87B▲ 105.4% | 2.43B▲ 29.9% | 8.86B▲ 264.4% | 8.56B▼ 3.3% | 6.42B▼ 25.0% | 5.77B▼ 10.2% | 5.63B▲ 0% |
Asset Turnover | 0.30x | 0.65x | 0.59x | 0.89x | 0.70x | 0.37x | 0.35x | 0.43x | 0.47x | 0.45x |
Asset Growth % | 140.89% | -13.78% | 12.96% | 105.43% | 29.89% | 264.38% | -3.31% | -24.99% | -10.19% | -44.27% |
Total Current Liabilities | 128.35M | 159.74M | 125.89M | 336.96M | 323.5M | 1.01B | 833.8M | 998.8M | 966.1M | 962.4M |
Accounts Payable | 27.28M | 25.17M | 26.7M | 86.32M | 101.5M | 283.3M | 294.8M | 246M | 279.4M | 243.5M |
Days Payables Outstanding | 81.88 | 44.48 | 45.52 | 100.72 | 88.15 | 77.76 | 71.7 | 60 | 70.04 | 75.59 |
Short-Term Debt | 20.18M | 54.38M | 12.66M | 0 | 300K | 207.5M | 139.8M | 341.8M | 178.3M | 228.2M |
Deferred Revenue (Current) | 62.37M | 63.56M | 336K | 3.73M | 1.9M | 76.4M | 36.8M | 33.5M | 0 | 74.3M |
Other Current Liabilities | 64.52M | 59.01M | 62.49M | 74.39M | 65.5M | 156.4M | 127.8M | 96.8M | 376.6M | 490.7M |
Current Ratio | 2.58x | 1.21x | 1.77x | 3.39x | 4.45x | 1.56x | 1.57x | 1.22x | 1.50x | 1.43x |
Quick Ratio | 2.06x | 0.79x | 1.30x | 3.05x | 3.84x | 1.04x | 0.88x | 0.69x | 0.90x | 0.80x |
Cash Conversion Cycle | 222.44 | 128.31 | 123.35 | 148.3 | 169.12 | 131.63 | 128.3 | 129.37 | 130.5 | 170.77 |
Total Non-Current Liabilities | 579.8M | 221.05M | 225.16M | 201.5M | 177.5M | 2.91B | 2.72B | 2.44B | 2.88B | 2.81B |
Long-Term Debt | 377.26M | 53.19M | 0 | 0 | 400K | 2.43B | 2.27B | 2.14B | 2.47B | 155.4M |
Capital Lease Obligations | 0 | 0 | 93.23M | 100.71M | 128.6M | 186.4M | 172.8M | 167.2M | 154.4M | 466.3M |
Deferred Tax Liabilities | 430K | 9.81M | 30.02M | 38.33M | 0 | 213.2M | 192.2M | 76.5M | 90M | 340.2M |
Other Non-Current Liabilities | 202.11M | 167.86M | 131.93M | 100.79M | 48.5M | 74.4M | 83.6M | 38M | 166.4M | 2.57B |
Total Liabilities | 708.15M | 380.79M | 351.05M | 538.46M | 501M | 3.92B | 3.56B | 3.44B | 3.85B | 3.78B |
Total Debt | 397.45M | 107.57M | 112.3M | 108.5M | 139.3M | 2.85B | 2.61B | 2.68B | 2.8B | 383.6M |
Net Debt | 361.36M | 63.87M | 59.52M | -381.44M | -663.5M | 2.56B | 2.5B | 2.58B | 2.63B | 243.2M |
Debt / Equity | 1.75x | 0.25x | 0.20x | 0.08x | 0.07x | 0.58x | 0.52x | 0.90x | 1.46x | 0.21x |
Debt / EBITDA | 9.86x | 0.76x | 0.80x | 0.10x | 0.15x | 2.53x | 4.38x | - | - | -0.59x |
Net Debt / EBITDA | 8.96x | 0.45x | 0.42x | -0.34x | -0.69x | 2.27x | 4.18x | - | - | -0.37x |
Interest Coverage | 0.54x | 3.61x | 6.22x | 831.31x | 1286.57x | 10.88x | 0.84x | -10.32x | -5.24x | -5.18x |
Total Equity | 227.1M▲ 0% | 425.58M▲ 87.4% | 559.82M▲ 31.5% | 1.33B▲ 138.1% | 1.93B▲ 44.8% | 4.93B▲ 155.8% | 5.01B▲ 1.4% | 2.98B▼ 40.4% | 1.92B▼ 35.7% | 1.85B▲ 0% |
Equity Growth % | 13.2% | 87.4% | 31.54% | 138.06% | 44.77% | 155.76% | 1.44% | -40.38% | -35.65% | -121.98% |
Book Value per Share | 6.73 | 10.00 | 12.99 | 30.57 | 45.00 | 85.97 | 74.94 | 44.41 | 28.33 | 27.15 |
Total Shareholders' Equity | 227.1M | 425.58M | 559.82M | 1.33B | 1.93B | 4.93B | 5.01B | 2.98B | 1.92B | 1.85B |
Common Stock | 35K | 39K | 42K | 42K | 0 | 0 | 100K | 100K | 0 | 100K |
Retained Earnings | -12.42M | 61.76M | 134.68M | 944.97M | 1.65B | 2.2B | 2.19B | 135.8M | 0 | -1.09B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -139K | -463K | -431K | 400K | -67.6M | -30M | -36.2M | 0 | -4.1M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QDEL Cash Flow Statement
QuidelOrtho Corporation (QDEL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Jan'23 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 27.71M | 136.34M | 134.49M | 629.76M | 805.87M | 885.3M | 280.2M | 83M | 105.2M | 6.6M |
Operating CF Margin % | 9.98% | 26.11% | 25.14% | 37.9% | 47.44% | 27.11% | 9.35% | 2.98% | 3.85% | - |
Operating CF Growth % | 134.52% | 392.06% | -1.36% | 368.28% | 27.96% | 9.86% | -68.35% | -70.38% | 26.75% | -129.64% |
Net Income | -8.16M | 74.18M | 72.92M | 810.29M | 704.23M | 548.7M | -10.1M | -2.05B | -1.13B | -1.21B |
Depreciation & Amortization | 30.76M | 46.27M | 47.83M | 49.09M | 54.38M | 283.6M | 457.2M | 453.4M | 442M | 447.8M |
Stock-Based Compensation | 9.06M | 11.71M | 13.25M | 21.02M | 25.4M | 48.4M | 51.6M | 42.1M | 0 | 23.5M |
Deferred Taxes | 365K | -20.46M | -1.74M | -20.21M | 24.67M | 0 | 0 | -99.3M | 6.3M | 5.3M |
Other Non-Cash Items | 19.5M | 26.98M | 17.47M | 20.65M | -34K | 57.8M | -23.6M | 1.9B | 914.5M | 821.3M |
Working Capital Changes | -23.81M | -2.33M | -15.24M | -251.07M | -2.78M | -53.2M | -194.9M | -158.7M | -125.8M | -80.4M |
Change in Receivables | -42.05M | 8.24M | -36.06M | -402.09M | 118.85M | 150.2M | 160M | 5.4M | -117.5M | -119.7M |
Change in Inventory | 362K | -3.97M | 9.14M | -54.9M | -85.04M | -116.9M | -211.6M | -134.1M | -148.3M | -95.2M |
Change in Payables | 12.96M | -331K | 2.43M | 52.23M | 10.45M | 23.5M | 3M | -23.4M | 40M | 41.3M |
Cash from Investing | -431.76M | 114.95M | -27.23M | -63.32M | -319.53M | -1.64B | -187.6M | -149.9M | -192.7M | -170.5M |
Capital Expenditures | -17.51M | -31.69M | -27.23M | -64.93M | -292.72M | -140.9M | -209.3M | -195.1M | -188.2M | -88M |
CapEx % of Revenue | 6.3% | 6.07% | 5.09% | 3.91% | 17.23% | 4.31% | 6.98% | 7.01% | 6.89% | 3.31% |
Acquisitions | -414.25M | 146.64M | 0 | 0 | 0 | -1.51B | 0 | 0 | 6.5M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 146.64M | 0 | 1.6M | 36.88M | 18.4M | 3.5M | -10.7M | -11M | -82.5M |
Cash from Financing | 270.61M | -244.06M | -98.28M | -130.28M | -173.18M | 252M | -265.8M | 48.8M | 155.8M | 175.8M |
Debt Issued (Net) | 254.9M | -201.94M | -53.56M | -43.96M | -300K | 346.2M | -226.4M | 53.4M | 155.1M | 139.1M |
Equity Issued (Net) | 24.89M | 12.7M | 14.78M | -38.28M | -95.89M | -47.9M | 4.4M | 5M | 6.1M | 3.1M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -541K | -4.34M | 0 | -43.69M | -103.44M | -74.3M | -7.2M | 0 | 0 | 0 |
Other Financing | -9.18M | -54.82M | -59.51M | -48.04M | -76.99M | -46.3M | -43.8M | -9.6M | -5.4M | 33.6M |
Net Change in Cash | -133.42M▲ 0% | 7.61M▲ 105.7% | 9.08M▲ 19.3% | 437.17M▲ 4714.6% | 312.81M▼ 28.4% | -508.9M▼ 262.7% | -174.4M▲ 65.7% | -21M▲ 88.0% | 71.3M▲ 439.5% | 13.2M▲ 0% |
Free Cash Flow | 10.2M▲ 0% | 104.66M▲ 926.1% | 107.26M▲ 2.5% | 564.84M▲ 426.6% | 513.14M▼ 9.2% | 744.4M▲ 45.1% | 70.9M▼ 90.5% | -112.1M▼ 258.1% | -83M▲ 26.0% | -75.2M▲ 0% |
FCF Margin % | 3.67% | 20.04% | 20.05% | 33.99% | 30.21% | 22.79% | 2.37% | -4.03% | -3.04% | -2.83% |
FCF Growth % | 10950% | 926.14% | 2.48% | 426.62% | -9.15% | 45.07% | -90.48% | -258.11% | 25.96% | -347.37% |
FCF per Share | 0.30 | 2.46 | 2.49 | 12.96 | 11.97 | 12.97 | 1.06 | -1.67 | -1.22 | -1.10 |
FCF Conversion (FCF/Net Income) | -3.39x | 1.84x | 1.84x | 0.78x | 1.14x | 1.61x | -27.74x | -0.04x | -0.09x | 0.06x |
Interest Paid | 9.14M | 7.93M | 2.29M | 500K | 0 | 95.1M | 150M | 177.5M | 0 | 0 |
Taxes Paid | 1.27M | 6.92M | 2.19M | 109.91M | 235.6M | 264.8M | 86.6M | 177.5M | 0 | 0 |
QDEL Key Ratios
QuidelOrtho Corporation (QDEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -3.82% | 22.73% | 14.8% | 85.63% | 43.17% | 15.99% | -0.2% | -51.36% | -46.15% | -56.31% |
Return on Invested Capital (ROIC) | 1.87% | 13.35% | 12.54% | 101.27% | 61.29% | 14.45% | 1.39% | -22.51% | -13.62% | -17.5% |
Gross Margin | 56.22% | 60.45% | 59.98% | 81.17% | 75.26% | 59.28% | 49.94% | 46.23% | 46.67% | 56.6% |
Net Margin | -2.94% | 14.2% | 13.63% | 48.76% | 41.46% | 16.8% | -0.34% | -73.74% | -41.45% | -45.57% |
Debt / Equity | 1.75x | 0.25x | 0.20x | 0.08x | 0.07x | 0.58x | 0.52x | 0.90x | 1.46x | 0.21x |
Interest Coverage | 0.54x | 3.61x | 6.22x | 831.31x | 1286.57x | 10.88x | 0.84x | -10.32x | -5.24x | -5.18x |
FCF Conversion | -3.39x | 1.84x | 1.84x | 0.78x | 1.14x | 1.61x | -27.74x | -0.04x | -0.09x | 0.06x |
Revenue Growth | 44.96% | 88.05% | 2.41% | 210.66% | 2.22% | 92.28% | -8.21% | -7.17% | -1.89% | -3.89% |
Related:QDEL Dividend History·QDEL Revenue History·QDEL Price History·QDEL P/E History·QDEL Financial Ratios·QDEL Institutional Holders
QDEL SEC Filings & Documents
QuidelOrtho Corporation (QDEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
QDEL Frequently Asked Questions
QuidelOrtho Corporation (QDEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
QuidelOrtho Corporation (QDEL) reported $2.66B in revenue for fiscal year 2025. This represents a 7602% increase from $34.5M in 1995.
QuidelOrtho Corporation (QDEL) saw revenue decline by 1.9% over the past year.
QuidelOrtho Corporation (QDEL) reported a net loss of $1.21B for fiscal year 2025.
Dividend & Returns
QuidelOrtho Corporation (QDEL) has a return on equity (ROE) of -46.1%. Negative ROE indicates the company is unprofitable.
QuidelOrtho Corporation (QDEL) had negative free cash flow of $75.2M in fiscal year 2025, likely due to heavy capital investments.